Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Joseph Farris

Child & Adolescent Psychiatry Marion, OH Medical Doctor

NPI 1952321804 CMS profile 360541

990 S Prospect St Ste 3, Marion, OH 43302

Open in the dashboard

General payments

$1,810

121 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Joseph Farris of Marion, OH is reported in the CMS Open Payments database as having received $1,810 across 121 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $705 37
2022 General $420 33
2021 General $175 13
2020 General $213 17
2019 General $297 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Farris
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Joseph Farris were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Joseph Farris Child & Adolescent Psychiatry median Middle half National median
2019 $297 $129 $42–$419 $163
2020 $213 $81 $28–$226 $114
2021 $175 $115 $31–$326 $132
2022 $420 $124 $40–$382 $149
2023 $705 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $0 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $337 34 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $206 16 payments
  3. Supernus Pharmaceuticals, Inc. $179 10 payments
  4. Otsuka America Pharmaceutical, Inc. $170 7 payments
  5. Vertical Pharmaceuticals, LLC $169 12 payments
  6. Corium, Inc. $154 5 payments
  7. Tris Pharma Inc $122 9 payments
  8. Janssen Pharmaceuticals, Inc $99 5 payments
  9. Lundbeck LLC $76 4 payments
  10. Neurocrine Biosciences, Inc. $75 4 payments
  11. Other $223 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,799 120 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2023
  1. VRAYLAR $337 34 payments
  2. VYVANSE $231 18 payments
  3. QELBREE $179 10 payments
  4. RELEXXII $169 12 payments
  5. REXULTI Psychiatry $158 6 payments
  6. Azstarys $154 5 payments
  7. INVEGA SUSTENNA $99 5 payments
  8. INVEGA TRINZA $99 5 payments
  9. REXULTI Psychiatry $76 4 payments
  10. INGREZZA $75 4 payments
  11. Other $523 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

3,046

Median for Psychiatry: 574

Drug cost

$345,114

Median for Psychiatry: $27,624

Branded share of claims

23.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 58 $90,785
Rexulti Brexpiprazole Brand 37 $57,407
Wellbutrin Xl Bupropion Hcl Brand 14 $40,216
Abilify Maintena Aripiprazole Brand 13 $28,223
Trintellix Vortioxetine Hydrobromide Brand 50 $25,047
Caplyta Lumateperone Tosylate Brand 12 $19,619
Dayvigo Lemborexant Brand 25 $11,530
Aripiprazole Generic 85 $10,401
Vyvanse Lisdexamfetamine Dimesylate Brand 19 $7,291
Belsomra Suvorexant Brand 15 $6,488

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$18,909

Medicare's payments for the services billed

Medicare patients

88

Average age 58

Services billed

236

41 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 68%
Arthritis 50%
Diabetes 32%
COPD 25%
Ischemic heart disease 22%
Chronic kidney disease 22%
Alzheimer's or dementia 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record